A new trading day began on Monday, with C4 Therapeutics Inc (NASDAQ: CCCC) stock price down -4.87% from the previous day of trading, before settling in for the closing price of $2.67. CCCC’s price has ranged from $1.09 to $5.10 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -8.92%. Meanwhile, its annual earnings per share averaged 6.60%. With a float of $77.61 million, this company’s outstanding shares have now reached $96.91 million.
C4 Therapeutics Inc (CCCC) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of C4 Therapeutics Inc is 19.92%, while institutional ownership is 57.44%. The most recent insider transaction that took place on Feb 18 ’25, was worth 2,107. In this transaction Chief Business Officer of this company sold 669 shares at a rate of $3.15, taking the stock ownership to the 107,805 shares. Before that another transaction happened on Feb 14 ’25, when Company’s Chief Business Officer sold 490 for $3.15, making the entire transaction worth $1,544. This insider now owns 110,842 shares in total.
C4 Therapeutics Inc (CCCC) Earnings and Forecasts
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.49 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.60% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.38% during the next five years compared to -8.92% drop over the previous five years of trading.
C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators
Here are C4 Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.67, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.31 in one year’s time.
Technical Analysis of C4 Therapeutics Inc (CCCC)
Looking closely at C4 Therapeutics Inc (NASDAQ: CCCC), its last 5-days average volume was 2.33 million, which is a jump from its year-to-date volume of 1.59 million. As of the previous 9 days, the stock’s Stochastic %D was 48.71%.
During the past 100 days, C4 Therapeutics Inc’s (CCCC) raw stochastic average was set at 34.71%, which indicates a significant decrease from 45.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.19 in the past 14 days, which was lower than the 0.22 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.42, while its 200-day Moving Average is $2.09. However, in the short run, C4 Therapeutics Inc’s stock first resistance to watch stands at $2.70. Second resistance stands at $2.87. The third major resistance level sits at $2.97. If the price goes on to break the first support level at $2.43, it is likely to go to the next support level at $2.33. Should the price break the second support level, the third support level stands at $2.16.
C4 Therapeutics Inc (NASDAQ: CCCC) Key Stats
With a market capitalization of 246.16 million, the company has a total of 96,914K Shares Outstanding. Currently, annual sales are 35,580 K while annual income is -105,320 K. The company’s previous quarter sales were 11,230 K while its latest quarter income was -32,170 K.
